Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020154315 - METHODS FOR TREATING SCHIZOPHRENIA

Publication Number WO/2020/154315
Publication Date 30.07.2020
International Application No. PCT/US2020/014461
International Filing Date 21.01.2020
IPC
A61K 31/519 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61K 9/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
A61P 25/18 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Applicants
  • INDIVIOR UK LIMITED [GB]/[GB]
Inventors
  • HEIDBREDER, Christian, A.
  • ANDORN, Anne, C.
  • GRAHAM, James, A.
Agents
  • GRIEFF, Edward D.
  • ADAMS, Lisa
  • AZRIN, Linda B.
  • ALLISON, William F.
  • AMENDT, Kevin C.
Priority Data
62/795,26022.01.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR TREATING SCHIZOPHRENIA
(FR) MÉTHODES DE TRAITEMENT DE LA SCHIZOPHRÉNIE
Abstract
(EN)
The disclosure provides methods for treating negative, positive, and general symptoms of schizophrenia in patients using long-acting, injectable antipsychotic drugs. The disclosure provides methods of treating a negative symptom in a schizophrenic patient in need thereof by administering to the patient a therapeutically effective amount of a risperidone composition; wherein the risperidone composition comprises about 120 mg of risperidone base.
(FR)
L'invention concerne des méthodes de traitement de symptômes négatifs, positifs et généraux de la schizophrénie chez des patients à l'aide de médicaments antipsychotiques injectables à action prolongée. L'invention concerne des méthodes de traitement d'un symptôme négatif chez un patient souffrant de schizophrénie qui en a besoin par l'administration au patient d'une quantité thérapeutiquement efficace d'une composition de rispéridone; la composition de rispéridone comprenant environ 120 mg de la base rispéridone.
Latest bibliographic data on file with the International Bureau